Vijay T. Alagappan
BioPharmaceuticals R&D, Respiratory And Immunology, AstraZeneca
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Respiratory medicine
Published: March 24, 2022
Reply to "As-needed budesonide-formoterol for adolescents with mild asthma: importance of lung function".
Journal: The journal of allergy and clinical immunology. In practice
Published: August 20, 2021
Positioning As-needed Budesonide-Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2.
Journal: Annals of the American Thoracic Society
Published: May 12, 2021
Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma.
Journal: The journal of allergy and clinical immunology. In practice
Published: October 26, 2020
Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
Journal: The Lancet. Respiratory medicine
Published: July 10, 2020
Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Journal: The Lancet. Respiratory medicine
Published: May 29, 2018
Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
Journal: American journal of respiratory and critical care medicine
Published: May 16, 2018
Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: September 02, 2016
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Journal: The Lancet. Respiratory medicine
Published: December 11, 2013
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
Journal: The European respiratory journal
Published: November 02, 2013
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Journal: International journal of chronic obstructive pulmonary disease
Published: October 26, 2013
Last Updated: 09/26/2026